HC Wainwright Issues Pessimistic Estimate for YMAB Earnings

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) – HC Wainwright lowered their Q2 2025 earnings estimates for shares of Y-mAbs Therapeutics in a report issued on Monday, May 19th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.23) per share for the quarter, down from their prior forecast of ($0.22). HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Y-mAbs Therapeutics’ current full-year earnings is ($0.65) per share. HC Wainwright also issued estimates for Y-mAbs Therapeutics’ Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.24) EPS, FY2025 earnings at ($0.80) EPS, Q1 2026 earnings at ($0.24) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at ($0.22) EPS and Q4 2026 earnings at ($0.23) EPS.

Other research analysts have also issued research reports about the stock. Oppenheimer reduced their target price on shares of Y-mAbs Therapeutics from $21.00 to $20.00 and set an “outperform” rating on the stock in a research note on Wednesday, May 14th. Wedbush reaffirmed an “outperform” rating and issued a $23.00 target price on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Morgan Stanley cut their price target on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating on the stock in a research report on Wednesday, March 5th. Bank of America downgraded shares of Y-mAbs Therapeutics from a “neutral” rating to an “underperform” rating and set a $3.00 price target on the stock. in a research report on Tuesday, April 22nd. Finally, Truist Financial cut their price target on shares of Y-mAbs Therapeutics from $18.00 to $14.00 and set a “buy” rating on the stock in a research report on Wednesday, May 14th. Two investment analysts have rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $16.60.

Y-mAbs Therapeutics Trading Down 3.1%

Shares of NASDAQ YMAB opened at $4.10 on Wednesday. The firm has a market capitalization of $185.66 million, a PE ratio of -7.59 and a beta of 0.53. Y-mAbs Therapeutics has a 1 year low of $3.55 and a 1 year high of $16.11. The firm’s 50-day moving average is $4.43 and its 200-day moving average is $6.89.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.10. The company had revenue of $20.90 million for the quarter, compared to analyst estimates of $19.97 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%.

Insider Activity at Y-mAbs Therapeutics

In other Y-mAbs Therapeutics news, insider Thomas Gad sold 10,810 shares of the firm’s stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the sale, the insider now directly owns 202,721 shares in the company, valued at approximately $1,060,230.83. This trade represents a 5.06% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. 22.50% of the stock is currently owned by corporate insiders.

Institutional Trading of Y-mAbs Therapeutics

Hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN raised its holdings in Y-mAbs Therapeutics by 54.1% during the 4th quarter. Wells Fargo & Company MN now owns 17,458 shares of the company’s stock worth $137,000 after buying an additional 6,131 shares during the period. JPMorgan Chase & Co. raised its holdings in Y-mAbs Therapeutics by 10.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company’s stock worth $399,000 after buying an additional 2,854 shares during the period. Geode Capital Management LLC raised its holdings in Y-mAbs Therapeutics by 1.1% during the 4th quarter. Geode Capital Management LLC now owns 822,309 shares of the company’s stock worth $6,440,000 after buying an additional 8,820 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Y-mAbs Therapeutics by 1.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 284,540 shares of the company’s stock worth $2,228,000 after buying an additional 4,963 shares during the period. Finally, KLP Kapitalforvaltning AS acquired a new stake in Y-mAbs Therapeutics during the 4th quarter worth approximately $46,000. 70.85% of the stock is currently owned by institutional investors and hedge funds.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.